0001104659-22-093714.txt : 20220823
0001104659-22-093714.hdr.sgml : 20220823
20220823163057
ACCESSION NUMBER: 0001104659-22-093714
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220819
FILED AS OF DATE: 20220823
DATE AS OF CHANGE: 20220823
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cramer Pamela J.
CENTRAL INDEX KEY: 0001873517
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38223
FILM NUMBER: 221187899
MAIL ADDRESS:
STREET 1: C/O RHYTHM PHARMACEUTICALS
STREET 2: 222 BERKELEY STREET, SUITE 1200
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RHYTHM PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001649904
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 462159271
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 857-264-4280
MAIL ADDRESS:
STREET 1: 222 BERKELEY STREET
STREET 2: 12TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: RHYTHM METABOLIC, INC.
DATE OF NAME CHANGE: 20150803
4
1
tm2224302-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-08-19
0
0001649904
RHYTHM PHARMACEUTICALS, INC.
RYTM
0001873517
Cramer Pamela J.
222 BERKELEY STREET, 12TH FLOOR
BOSTON
MA
02116
0
1
0
0
Chief Human Resources Officer
Common Stock
2022-08-19
4
M
0
13493
19.02
A
15717
D
Common Stock
2022-08-19
4
S
0
13493
24.83
D
2224
D
Stock Option (Right to Buy)
19.02
2022-08-19
4
M
0
13493
0
D
2031-07-25
Common Stock
13493
61507
D
The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $24.79 to $24.86. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
The stock options were granted on July 26, 2021. 25% of the shares subject to the option vest and became exercisable on July 26, 2022 and the remaining 75% of the shares subject to the option vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.
/s/ Hunter Smith, attorney-in-fact for Pamela J. Cramer
2022-08-23